Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.75 |
| ▸ | F3 | P13726 | 1/20 | 0.75 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | NHERF1 | O14745 | 6/20 | 0.55 |
| ▸ | PYGL | P06737 | 1/20 | 0.55 |
| ▸ | GABRP | O00591 | 2/20 | 0.52 |
| ▸ | GABRD | O14764 | 2/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.52 |
| ▸ | GABRE | P78334 | 2/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2535534 | 0.87 | F7 (0.71) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL26204498 | 0.86 | NR4A2 (0.65) | F7F3NR4A2ALDH1A1ATM | |
| SCHEMBL1434913 | 0.86 | F7 (1.00) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL592274 | 0.84 | F7 (0.77) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL5912617 | 0.83 | F7 (0.75) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL2535532 | 0.81 | F7 (0.73) | F7F3NR4A2NHERF1PYGL | |
| SCHEMBL3443344 | 0.81 | F7 (0.73) | F7F3NR4A2ALDH1A1NHERF1 | |
| SCHEMBL2546826 | 0.81 | ALDH1A1 (0.61) | F7F3NR4A2ALDH1A1ATM | |
| SCHEMBL3389562 | 0.81 | ALDH1A1 (0.61) | F7F3ALDH1A1ATM | |
| SCHEMBL31368069 | 0.80 | F7 (0.71) | F7F3NR4A2NHERF1PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004240-A1 | Indole Compounds | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | GLAXO GROUP LIMITED (GB) | 2009-11-12 | — | — | US | disclosed |
| US-20090203910-A1 | Deprotection of N-BOC compounds | ROCH PALO ALTO LLC | 2009-08-13 | — | — | US | disclosed |
| EP-2070899-A1 | Deprotection of N-BOC compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| CN-101456780-A | Deprotection of n-boc compounds | HOFFMANN LA ROCHE (CH) | 2009-06-17 | — | — | CN | disclosed |
| EP-2041127-A2 | INDOLE COMPOUNDS | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2041126-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006794-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006794-A1 | INDOLE COMPOUNDS HAVING AFFINITY TO THE EP1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006795-A2 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008006795-A2 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281152-A1 | Indole Compounds Having Affinity to the EP1 Receptor | PTGER1, PTGER2, PTGER3 | F7 3162/4885F3 225/4885NR4A2 701/4885 |
| US-20090203910-A1 | Deprotection of N-BOC compounds | NUCB2, TERT, CEL | F7 96/4885F3 881/4885NR4A2 1600/4885 |
| US-20100004240-A1 | Indole Compounds | IDO1, TPH1, IDO2 | F7 1269/4885F3 53/4885NR4A2 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.